Overview

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The standard or usual treatment for this disease is treatment with drugs and other treatments that may help to make a patient better or may improve their quality of life. This treatment is known as "best supportive care" (BSC). Although patients with best supportive care can feel better for some months, the cancer usually continues to grow.

Phase:

Phase 2

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab